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Velo-cardio-facial syndrome
Robert J. Shprintzena,b, Anne Marie Higginsa, Kevin Antshelc, Wanda Fremontc,
Nancy Roizend and Wendy Katesc
Purpose of review
Velo-cardio-facial syndrome has emerged from obscurity to
become one of the most researched disorders this past
decade. It is one of the most common genetic syndromes in
humans, the most common contiguous gene syndrome in
humans, the most common syndrome of cleft palate, and
the most common syndrome of conotruncal heart
malformations. Velo-cardio-facial syndrome has an
expansive phenotype, a factor reflected in the wide range of
studies that cover both clinical features and molecular
genetics. In this review, we cover multiple areas of research
during the past year, including psychiatric disorders,
neuroimaging, and the delineation of clinical features.
Recent findings
The identification of candidate genes for heart anomalies,
mental illness, and other clinical phenotypes has been
reported in the past year with a focus on TBX1 for cardiac
and craniofacial phenotypes and COMT and PRODH for
psychiatric disorders. The expansive phenotype of
velo-cardio-facial syndrome continues to grow with new
behavioral and structural anomalies reported. Treatment
issues are beginning to draw attention, although most
authors continue to focus on diagnostic issues.
Summary
Its high population prevalence, estimated to be as common
as 1:2000 has sparked a large amount of research, as has
the model the syndrome serves for identifying the causes of
mental illness and learning disabilities, but it is obvious that
more information is needed. Intensive scrutiny of
velo-cardio-facial syndrome will undoubtedly continue for
many years to come with the hope that researchers will turn
more of their attention to treatment and treatment outcomes.
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Introduction
Velo-cardio-facial syndrome (VCFS) has emerged from a
relatively obscure multiple anomaly syndrome to one of
the most researched and well-studied disorders over the
past decade. Although initially delineated and named in
1978 [1], the same disorder was described earlier by many
authors and initial documentation of the same disorder
appears as early as 1955 [2,3]. Relatively few publications
appeared before 1992 when two events sparked interest in
the syndrome, the first being the discovery of a microde-
letion from the long arm of chromosome 22 at the q11.2
band [4–6] and the second being a report of a high fre-
quency of mental illness as a clinical feature [7]. Since
1992, there have been many publications focusing on the
genetics of the syndrome, the phenotypic spectrum, and
studies of cognition and mental illness. What has become
clear is that VCFS is the most common microdeletion syn-
drome in humans, the most common syndrome of cleft
palate, and the most common syndrome associated with
conotruncal heart anomalies. Learning disorders are nearly
ubiquitous in the syndrome, and immune disorders, speech
and language impairment, and behavioral abnormalities
occur in most cases. Therefore, essentially every case with
VCFS will present to pediatricians with multiple prob-
lems. The recent literature reflects much of this variabil-
ity of clinical presentation, although there has been little
emphasis on treatment. To date, there has been a major
emphasis on phenotype to genotype correlations to isolate
the direct causes of the various phenotypes in VCFS, and
on the continuing expansion of the phenotype. The devel-
opment of fluorescent in-situ hybridization testing (FISH)
for the disorder in the mid-1990s has resulted in a large
number of diagnoses worldwide that has sparked increased
clinical and research investigations of the disorder. There
have been at least 78 journal articles published during the
period of this review (slightly more than a year) that direc-
tly discuss VCFS, although there are many more articles
that indirectly mention aspects of the disorder or discuss
VCFS within the context of similar disorders. We will




The name ‘velo-cardio-facial syndrome’ was added to the
genetics lexicon in 1978 [1], but not all clinicians and
researchers use this term to designate the disorder caused
by a deletion at 22q11.2. Alternative names for this disor-
der include DiGeorge syndrome or DiGeorge sequence,
conotruncal anomalies face syndrome, Cayler syndrome,
22q11 deletion syndrome, and Sedlacˇkova´ syndrome [8•,9].
Although many clinicians believe that it is possible to
express VCFS in the absence of a detectable deletion of
22q11.2, recent publications have suggested that so-called
‘nondeleted’ cases are actually clinical diagnostic errors
rather than absent positive FISH findings. Although some
publications have continued to perpetuate the notion that
several different disorders are caused by the exact same
deletion from chromosome 22 [10], it is now clear that
the broad phenotype of VCFS manifests many possible
expressions that overlap with other conditions [8•,9,11].
Phenotypic descriptions
Although VCFS has been extensively described for more
than 25 years, new phenotypic descriptions continue to
be published as larger numbers of subjects are examined
by larger numbers of clinician scientists. Over the past
year, the publications have focused primarily on behavioral
and central nervous system phenotypes with smaller num-
bers of articles related to heart, immunologic, and otolar-
yngologic manifestations.
Behavioral and brain anomalies
VCFS displays a wide spectrum of developmental, neuropsy-
chological, and psychiatric manifestations. The detection of
these disorders may depend on the age and ascertainment
of the samples of subjects studied. For example, although
the average age of onset of psychosis in VCFS has been
reported to be approximately 21 years of age, similar to that
in the general population [12], studies reporting behav-
ioral abnormalities in children have not reported longitu-
dinal data to determine if early disorders such as attention
deficit disorder (ADD)/attention deficit hyperactivity dis-
order (ADHD) and obsessive-compulsive disorder (OCD)
predict subsequent psychosis [13]. It has been suggested
that the frequency of early onset psychosis in VCFS is not
particularly high compared with the general population,
although these data are far from conclusive [14].
Several investigators in previous years have hypothesized a
relation between a polymorphism in the COMT gene that
is located in the 22q11.2 critical region for VCFS and is
always deleted in the syndrome. COMT degrades synaptic
dopamines in the brain. Two polymorphisms in COMT
have been reported; a low activity allele (COMT158met)
and a high activity allele (COMT158val) [10] and the asso-
ciation of the most severe form of mental illness in adults
with VCFS has been with the COMT158met allele [15,16].
Although data to date that report the COMT genotype in
psychotic adults with VCFS has uniformly shown such
individuals to have a single copy of the COMT158met allele,
one report has suggested that the COMT158val allele may
result in more psychopathology, although the cases stud-
ied were younger children and psychosis was not diag-
nosed in the sample [13]. The same author found that
presence of the COMT158met allele in individuals with
VCFS performed better on tests of executive functioning
based on standardized neuropsychological testing [17].
Others have implicated additional genes in the deleted
region as possible candidates for psychosis in addition to
COMT, including PRODH [18,19] and ARVCF [20], which
is adjacent to COMT, but to date, these hypotheses have
not been confirmed and the major focus has remained on
COMT. What is clear to investigators is that VCFS repre-
sents an important model for studying mental illness
because a high percentage of affected individuals have
psychiatric illness [21] leading to the conclusion that
one or more genes in the deleted region must play an
important role in the development of mental illness
[22,23].
Studies of cognitive function using a variety of standard-
ized instruments have been reported from a number of
centers around the world, including the US, Israel, and
Europe [24–31]. An important question that is just begin-
ning to be addressed is the relation between cognitive
impairments and mental illness [24], although most reports
have been focused on developmental and learning disabil-
ities [27,28,31] and attentional or behavioral characteris-
tics such as ADD/ADHD and OCD [25,26,29,30]. Reports
consistently show that attentional problems are the most
common finding in children with VCFS, but that OCD
and other behavioral disorders are also common, including
generalized anxiety, phobias, and mood disorders.
A number of other studies have taken this process one-
step further by combining standardized neuropsycholog-
ical testing with sophisticated quantitative and/or func-
tional imaging of the brain [32–35,36••]. In the reports
studying brain anatomy and function a wide variety of
areas are implicated in the behavioral and cognitive prob-
lems associated with VCFS including frontal deep white
matter [32], the caudate nucleus [32], the prefrontal cor-
tex [32,33], increased sulcal cerebrospinal fluid in the
temporal and posterior brain [34], the cingulate gyrus [35],
and total brain volume [32–34,36••]. One report notes a
more significant decrease in brain volume and cognitive
performance in subjects with VCFS who have schizophre-
nia versus those who do not [36••]. Other researchers have
found abnormalities of the corpus callosum [37,38], poly-
microgyria [39], and pachygyria [40] based on neuroimag-
ing studies. Two quantitative magnetic resonance imaging
studies found increased size of the corpus callosum, one in
a small sample of 13 subjects and 13 controls [37], and a
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second in a large sample of 60 VCFS subjects matched to
52 age- and gender-matched control subjects [38]. Across
all measures, children with VCFS demonstrated a larger
corpus callosum area, although VCFS with ADHD had
smaller corpus callosum than children with VCFS without
ADHD did (although still larger than controls). It was
concluded that corpus callosum anomalies could be of
importance in determining brain–behavior relations in VCFS.
Also noted, as in previous reports, is a very high frequency
of cavum septum pellucidum, a finding also common in
individuals with schizophrenia [37]. Clearly, brain anom-
alies also cover a wide spectrum, as do other physical
anomalies in VCFS.
Heart anomalies
Early in the syndromic delineation of VCFS, publications
documenting heart anomalies constituted a larger percent-
age of the total literature. Today, VCFS is one of the most
frequently recognized syndromes associated with congen-
ital heart disease (CHD) and in most centers all babies
with tetralogy of Fallot, interrupted aortic arch type B,
truncus arteriosus, and other structural heart anomalies
combined with right-sided aortic arch are screened for
VCFS with FISH. In short, there are fewer surprises
and discoveries related to VCFS in relation to CHD. How-
ever, small numbers of publications continue to appear.
Some of these articles are reports of single cases or series
of cases describing clinical findings [41–43]. More inter-
esting is a report of how the diagnosis of VCFS affects
heart surgery outcomes [44]. Comparing infants with VCFS
and CHD to those with Down syndrome, other genetic
syndromes, and nonsyndromic cases of CHD, the highest
mortality rate was seen in children with VCFS. Heart
anomalies have also played a role in prenatal diagnosis
[45]. The increased application of high-level ultrasonic
examinations of the fetus will undoubtedly increase the
number of prenatal detections of VCFS, necessitating
obstetricians to know the phenotypic spectrum of VCFS
so that FISH can be applied when appropriate.
Immune disorders
Immune deficiency is not among the most common anom-
alies in VCFS, but the problem is one of the most difficult
to contend with for affected individuals and their families.
Reports on immunologic and associated endocrine disor-
ders have covered the age spectrum, from the neonatal
period to adult life. A series of five infant cases with rash,
lymphadenopathy, and Tcell abnormalities were described,
including two who died [46]. The patients developed the
rash, lymphadenopathy, and oligoclonal T cells in a sto-
chastic fashion. All patients had oligoclonal expansions
in more than 50% of T-cell receptor B variable (TCRBV)
families. The implication for proper management of such
cases was stressed in relation to making the primary diag-
nosis, especially because two of the children did not have
CHD.
At the other end of the age spectrum is a report of a
32-year-old man with hypoparathyroidism who was not
diagnosed until that age [47]. He had many of the clinical
features of VCFS, but of interest, his hypocalcemia and
hypoparathyroidism were not evident until after puberty.
Late detections of this type raise interesting questions
about the prevalence of VCFS in the general population,
as well as the natural history of the disorder. Another study
of immune response in VCFS including adult subjects sug-
gested that T cell counts in adults with VCFS are often
robust even in the presence of earlier deficiencies [48•].
It was hypothesized that reduced thymic production can
result in compensation by peripheral proliferation [48•].
This observation is consistent with the clinical observation
of a generally improving immune response in individuals
with VCFS over time.
The issue of live viral vaccines in VCFS is one that is often
asked by parents of children with VCFS. Two recent pub-
lications have addressed this issue [49•,50]. In a study of
14 children with ‘DiGeorge syndrome’ who were given the
measles, mumps, and rubella (MMR) vaccine, no adverse
reactions were noted and there was a positive antibody
response to the vaccines in the subjects [49•]. The study
did not report if the subjects were FISH positive for
22q11.2 deletion, but 12 of the 14 cases were said to have
typical craniofacial findings and developmental delay. An
editorial [50] strikes a somewhat more cautious note on
the administration of live viral vaccines suggesting that
there are immunodeficient cases of ‘DiGeorge’ that might
be at risk.
Cutting-edge treatments for immunodeficiency have also
been addressed recently [51,52]. Thymic transplant was
reported in six cases [51], one with 22q11.2 deletion and
another apparently clinically diagnosed with VCFS, but
reported to be negative by FISH testing for the deletion.
Therefore, only one of the subjects actually had VCFS.
The one patient with the deletion did not have CHD.
Although one of the cases subsequently died, the patient
with the deletion survived and was nearly 3 years post trans-
plant at the time of publication. Immune function was
improved, but there is obviously no control data to determine
if values would have been different without the transplant.
In another report, a single case of ‘DiGeorge syndrome’
was treated for cytomegalovirus infection using cord stem
cell transplantation with dramatic improvement. The
report did not mention if the patient had 22q11 deletion.
Other phenotypic findings
A number of other reports have documented a series of
anomalies in reports of single or multiple cases. Esopha-
geal atresia and tracheoesophageal fistula [53], single cen-
tral incisor [54], Brown syndrome [55], ocular anomalies
[55–57], Graves disease [58,59], seizures [60], broncho-
malacia [61], and vascular anomalies of the neck [62] were
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all described although most of these findings are not new
[52,55–62]. The presence of a single central incisor is of
interest because of previous associations of VCFS with
holoprosencephaly and the presence of esophageal atresia
or tracheoesophageal fistula points out the phenotypic
overlap of VCFS with other conditions such as VATER,
VACTERL, and Opitz syndrome.
Population studies
The incidence and prevalence of VCFS have been cited in
many studies, ranging from 1:2000 [8•] to 1:6000 [23].
The reasons for these discrepancies may be related to
methods of ascertainment, but are also probably affected
by the ability to recognize the syndrome. Because the major
entry point to diagnosis is CHD and at least 25% of indi-
viduals with VCFS do not have heart anomalies, many esti-
mates are probably artificially low. In a population study
based in Western Go¨taland, Sweden [63], a population
prevalence of 13.2 per 100 000 (or 1:7575) was calculated
based on all cases under 16 years of age diagnosed with
VCFS by FISH compared with the total number of births
in the region below the same age. However, the study did
not account for the possibility that many cases were not
recognized and referred for FISH, thus undoubtedly
resulting in underdetection. All referrals for the FISH
studies came from tertiary specialists, such as cardiolo-
gists, pediatric neurologists, child psychiatrists, immunol-
ogists, audiologists, and speech pathologists. It is notable
that geneticists were not among the referral sources.
In Israel, a cohort of 634 individuals with schizophrenia
was screened for 22q11.2 deletions [64]. Positive findings
for the deletion were found for 1% of the sample (six
cases). The authors note that this frequency is at least 40
times higher than the frequency of the syndrome in the
general population, thus confirming the increased risk
of mental illness in VCFS. In a similar study among
Afrikaners in South Africa, a 2% frequency of VCFS was
found among a sample of 85 schizophrenics [65].
In their screening of a sample of cases with conotruncal
heart anomalies in Germany [66], investigators searched
for somatic mutations among individuals with VCFS and
those without, obtaining heart tissues and thymus for
analysis. It is noted that of 23 patients with conotruncal
anomalies who were having surgery, nine had VCFS.
Following a different tact, a sample of patients from
Athens, Greece was screened with FISH if they had phe-
notypes the investigators considered consistent with
VCFS [67]. Seventeen of 139 patients were positive for
the deletion (12.2%). These data suggest a lack of famil-
iarity with the overall ‘gestalt’ of the VCFS phenotype.
In a more limited sample, but a more genetically homoge-
neous one, investigators performed a careful phenotypic
analysis of 17 individuals from two large kindreds [68].
They found that only 46% of the affected individuals
had CHD. There are several ways these data may be inter-
preted. Perhaps both families had epigenetic factors that
predisposed them from developing CHD. Conversely, it
may be that this pure ascertainment from related individ-
uals may actually represent a truer picture of the frequency
of CHD. Diagnosis in all family members was more easily
made and therefore milder cases did not escape detection.
Genomics
The large majority of individuals with VCFS have a dele-
tion of three million base pairs containing dozens of genes.
The challenge has been to determine how much of the
extensive phenotype can be traced back to one or more
of these genes. Many investigators now believe that dele-
tion of the gene TBX1 is responsible for the cardiac and
vascular findings and perhaps other anomalies traced to
the neural crest [69–72]. Other genes have also been
implicated in the anomalies found in VCFS, including
DGCR8 [73] and HIRA [74]. It has also been reported that
a regulatory effect that accounts for malformations in
VCFS is the inactivation of TGFß signaling in the neural
crest stem cells [75]. The mechanism of spontaneous rear-
rangements at 22q11.2, originally described several years
ago, was confirmed in another study demonstrating a
recombination error in stage 1 of meiosis [76]. The unique
arrangement of 22q11.2 that makes it a hot spot for rear-
rangement has been traced as an evolutionary change in
the structure of human DNA as described in a 2003 study
by Babcock and colleagues from the Albert Einstein Col-
lege of Medicine. The ‘hot’ nature of the region is further
illustrated by a report of first cousins who both had
de-novo deletions at 22q11.2 [77].
The question of phenotypic expression in relation to the
size of the deletion was also raised in a report analyzing
deletion size in familial cases [78]. Analysis of 10 families
with more than one generation of individuals with VCFS
showed that 70% had the smaller 1.5 Mb deletion, whereas
the large majority of individuals with VCFS (approximately
90%) have the more common 3 Mb deletion. The potential
for milder effect resulting in increased likelihood of repro-
duction is raised by these data, even with the small sample
size of the study.
Miscellaneous studies
With the major focus on the genetics of VCFS, other fac-
tors that might contribute to the outcome of child devel-
opment and temperament were explored within a family
context [79]. Improved emotional stability and reduced
irritability in children with VCFS was seen when parents
showed warmth rather than anger towards their children.
Although the root causes of personality traits in children
are complex, this report may help to turn an appropriate
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focus on family dynamics, especially when one child has
a significant developmental disorder.
In a survey of pediatricians and teachers in Northern and
Central California, researchers found that knowledge and
recognition of VCFS among the sample was poorer than
that for fragile X and Down syndrome [80•]. Because both
teachers and pediatricians make important decisions about
the management of children with VCFS, this study points
out the need for additional access to information for these
individuals.
Conclusion
VCFS is a common genetic disorder that is seen in all
aspects of pediatric practice from general primary care to ter-
tiary specialties. Its high population prevalence, estimated to
be as common as 1:2000 has sparked a large amount of
research, as has the model the syndrome serves for iden-
tifying the causes of mental illness and learning disabilities,
but it is obvious that more information is needed [80•].
Intensive scrutiny of VCFS will undoubtedly continue
for many years to come with the hope that researchers will
turn more of their attention to treatment and treatment
outcomes.
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This survey study is of critical importance because it points out where we need to
do a better job if we are to improve the lot of people with VCFS. Organizations like
The Velo-Cardio-Facial Syndrome Educational Foundation should take note and
some degree of satisfaction in reading the article because it reinforces their goal
of public and professional education.
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